Nature Reviews Neurology

Papers
(The TQCC of Nature Reviews Neurology is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-02-01 to 2024-02-01.)
ArticleCitations
Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?1148
Perivascular spaces in the brain: anatomy, physiology and pathology376
Technology of deep brain stimulation: current status and future directions311
Protein transmission in neurodegenerative disease310
Lifting the mask on neurological manifestations of COVID-19305
Recovery from disorders of consciousness: mechanisms, prognosis and emerging therapies251
Parkinson disease and the immune system — associations, mechanisms and therapeutics241
Applications of machine learning to diagnosis and treatment of neurodegenerative diseases237
Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities235
Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities213
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders205
Applications of focused ultrasound in the brain: from thermoablation to drug delivery192
Blood GFAP as an emerging biomarker in brain and spinal cord disorders181
Diagnosis and management of migraine in ten steps170
Prodromal Parkinson disease subtypes — key to understanding heterogeneity161
Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease159
Multilevel omics for the discovery of biomarkers and therapeutic targets for stroke155
Peripheral and central immune system crosstalk in Alzheimer disease — a research prospectus154
Complement in neurological disorders and emerging complement-targeted therapeutics147
MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice143
Improving clinical trial outcomes in amyotrophic lateral sclerosis142
Cycles in epilepsy131
Neurological infection with SARS-CoV-2 — the story so far129
Developing the ATX(N) classification for use across the Alzheimer disease continuum127
The effects of the COVID-19 pandemic on people with dementia126
GAD antibodies in neurological disorders — insights and challenges124
The polygenic architecture of schizophrenia — rethinking pathogenesis and nosology116
An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders112
B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies101
Management of brain metastases according to molecular subtypes100
Post-traumatic stress disorder: clinical and translational neuroscience from cells to circuits99
Treatment and management of cognitive dysfunction in patients with multiple sclerosis98
Inflammation in acquired hydrocephalus: pathogenic mechanisms and therapeutic targets97
The human connectome in Alzheimer disease — relationship to biomarkers and genetics94
Virtual reality in research and rehabilitation of gait and balance in Parkinson disease93
Advances in local therapy for glioblastoma — taking the fight to the tumour92
Stroke in Africa: profile, progress, prospects and priorities92
Drug repositioning and repurposing for Alzheimer disease92
Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours90
Do infections have a role in the pathogenesis of Alzheimer disease?89
MicroRNAs as regulators of brain function and targets for treatment of epilepsy87
Metagenomics for neurological infections — expanding our imagination86
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility86
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic85
CRISPR-based functional genomics for neurological disease84
Circadian rhythms in neurodegenerative disorders82
Hypomyelinating leukodystrophies — unravelling myelin biology80
Spinal muscular atrophy — insights and challenges in the treatment era79
Status of peripheral sodium channel blockers for non-addictive pain treatment78
The neuroanatomical–functional paradox in spinal cord injury74
Non-neuronal cells in amyotrophic lateral sclerosis — from pathogenesis to biomarkers74
Synaptic degeneration in Alzheimer disease70
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders69
Apparent changes in the epidemiology and severity of multiple sclerosis67
Aducanumab and the FDA — where are we now?66
The importance of ongoing international surveillance for Creutzfeldt–Jakob disease63
Can we learn lessons from the FDA’s approval of aducanumab?62
The inter-relationship between delirium and dementia: the importance of delirium prevention62
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease61
The metabolic basis of epilepsy60
Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations59
Lung innervation in the eye of a cytokine storm: neuroimmune interactions and COVID-1959
Impact of predictive, preventive and precision medicine strategies in epilepsy58
White matter injury in infants with intraventricular haemorrhage: mechanisms and therapies57
Pharmacological brain cytoprotection in acute ischaemic stroke — renewed hope in the reperfusion era55
Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis55
Neurological immunotherapy in the era of COVID-19 — looking for consensus in the literature53
Hope for patients with neuromyelitis optica spectrum disorders — from mechanisms to trials52
Amyloid-β: a potential link between epilepsy and cognitive decline52
International consensus recommendations on the diagnostic work-up for malformations of cortical development51
Psychosis in Alzheimer disease — mechanisms, genetics and therapeutic opportunities51
Gene–environment interactions in Alzheimer disease: the emerging role of epigenetics50
Identification of clinically relevant biomarkers of epileptogenesis — a strategic roadmap50
Nodes of Ranvier during development and repair in the CNS50
Neurobehavioural comorbidities of epilepsy: towards a network-based precision taxonomy49
The role of glial cells in multiple sclerosis disease progression49
Alzheimer disease in African American individuals: increased incidence or not enough data?45
The B cell immunobiology that underlies CNS autoantibody-mediated diseases45
Hormonal influences in migraine — interactions of oestrogen, oxytocin and CGRP45
Mind the gap: from neurons to networks to outcomes in multiple sclerosis44
The multiple sclerosis prodrome44
Changing demography and the challenge of dementia in India43
The role of the gut microbiota in multiple sclerosis43
Functional roles of reactive astrocytes in neuroinflammation and neurodegeneration42
Multimodal brain and retinal imaging of dopaminergic degeneration in Parkinson disease42
Multi-target approaches to CNS repair: olfactory mucosa-derived cells and heparan sulfates41
Astrocytes in the initiation and progression of epilepsy41
MRI biomarkers in neuro-oncology40
Autonomic manifestations of epilepsy: emerging pathways to sudden death?40
Artificial intelligence for decision support in acute stroke — current roles and potential40
Cluster headache pathophysiology — insights from current and emerging treatments39
The approval of Aduhelm risks eroding public trust in Alzheimer research and the FDA39
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies39
Human cerebral organoids — a new tool for clinical neurology research38
Early-stage Alzheimer disease: getting trial-ready37
Global epidemiology of migraine and its implications for public health and health policy35
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications35
Perinatal stroke: mapping and modulating developmental plasticity34
Nuclear pore complexes — a doorway to neural injury in neurodegeneration32
Sex and gender in neurodevelopmental conditions31
COVID-19 and management of neuroimmunological disorders31
Refining oxytocin therapy for autism: context is key30
Cognitive adverse effects of chemotherapy and immunotherapy: are interventions within reach?29
Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus29
Drug-resistant epilepsy — time to target mechanisms28
Genetics of common cerebral small vessel disease28
Guillain–Barré syndrome in low-income and middle-income countries: challenges and prospects27
Rapidly progressive dementias — aetiologies, diagnosis and management27
Multifaceted microglia — key players in primary brain tumour heterogeneity27
Applying genomic and transcriptomic advances to mitochondrial medicine26
Review and update of the concept of embolic stroke of undetermined source25
hiPSCs for predictive modelling of neurodegenerative diseases: dreaming the possible25
Dissecting the complexities of Alzheimer disease with in vitro models of the human brain25
Vaccination and immunotherapies in neuroimmunological diseases25
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes24
The neurovascular unit and systemic biology in stroke — implications for translation and treatment24
Social determinants of health in multiple sclerosis24
Genetic testing in dementia — utility and clinical strategies24
‘Concussion’ is not a true diagnosis24
Positron emission tomography in multiple sclerosis — straight to the target23
Single-cell and spatial transcriptomics: deciphering brain complexity in health and disease23
Emerging therapies to target CNS pathophysiology in multiple sclerosis23
New insights into the neurological effects of COVID-1922
Prospective memory impairment in neurological disorders: implications and management22
Bruton tyrosine kinase inhibitors for multiple sclerosis22
From the prodromal stage of multiple sclerosis to disease prevention20
Neurological telemedicine in the COVID-19 era20
Inequities in neurology amplified by the COVID-19 pandemic19
Lecanemab trial in AD brings hope but requires greater clarity19
Neurogenetic disorders across the lifespan: from aberrant development to degeneration18
Neuropsychology’s race problem does not begin or end with demographically adjusted norms18
Cognitive impairment and World Trade Centre-related exposures18
Zoonotic and vector-borne parasites and epilepsy in low-income and middle-income countries18
Facing the urgency of therapies for progressive MS — a Progressive MS Alliance proposal17
Headache in people with epilepsy17
Counting the neurological cost of COVID-1916
Maximizing treatment efficacy through patient stratification in neuropathic pain trials16
Functional brain networks in the evaluation of patients with neurodegenerative disorders16
Closing the loop for patients with Parkinson disease: where are we?16
Gene therapy for primary mitochondrial diseases: experimental advances and clinical challenges16
Epigenetic genes and epilepsy — emerging mechanisms and clinical applications15
SARS-CoV-2 detected in olfactory neurons15
The childhood migraine syndrome15
Inflammation in multiple sclerosis: consequences for remyelination and disease progression14
Genetic generalized epilepsies in adults — challenging assumptions and dogmas14
Towards treating progressive multiple sclerosis14
Neurodegenerative diseases associated with non-coding CGG tandem repeat expansions14
A cultural approach to dementia — insights from US Latino and other minoritized groups14
Global synergistic actions to improve brain health for human development14
Neuroprognostication: a conceptual framework14
The role of astrocytic α7 nicotinic acetylcholine receptors in Alzheimer disease14
A global view of the genetic basis of Alzheimer disease14
Exosomal α-synuclein as a biomarker for Parkinson disease14
0.029939889907837